24 January 2019 | News
Engility CTMS is engineered for change and benefits from extensive automation to deliver new features in a regulated industry, faster than current products
PHARMASEAL provides clinical trial management platform and governance solutions to enter the market, has launched Engility™ CTMS, the first product to be released from its Engility B2B platform.
PHARMASEAL has industry expertise, innovative thinking and advanced automation to build and operate an integrated enterprise platform which allows biopharmaceutical and medical device companies to manage all of their clinical trials effectively.
With a focus on usability and rapid implementation, this innovative new generation clinical trial management system (CTMS) has been designed to increase the level of governance and control that organisations demand from their management systems to enable effective oversight of their clinical trials.
A key challenge to overcome in the design was to optimise the cost of software validation so that new innovations can be introduced easily for the benefit of customers. Engility CTMS is engineered for change and benefits from extensive automation to deliver new features in a regulated industry, faster than current products. With an intuitive interface and flexible cloud architecture, biopharmaceutical and medical device companies of all sizes can leverage affordable enterprise technology to fit their particular organisation model.